DGI:Ambulant erworbene Pneumonie/Quellen: Difference between revisions

From Infektiopedia
imported>Bestem
No edit summary
imported>Bestem
No edit summary
Line 1: Line 1:
*Hochspringen↑ Moore, M., et al., Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study. Eur Respir J, 2017. 50(5).
1. Almirall J, Bolíbar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004;125(4):1335-1342. doi:10.1378/chest.125.4.1335
*Hochspringen↑ Bauer, T.T., et al., CRB-65 predicts death from community-acquired pneumonia. J Intern Med, 2006. 260(1): p. 93-101.
*Hochspringen↑ Kolditz, M., et al., Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med, 2015. 278(2): p. 193-202.
*Hochspringen↑ Fine, M.J., et al., A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med, 1997. 336(4): p. 243-50.
*Hochspringen↑ Liapikou, A., et al., Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis, 2009. 48(4): p. 377-85.
*Hochspringen↑ Chalmers, J.D., et al., Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis, 2011. 53(6): p. 503-11.
*Hochspringen↑<nowiki>https://iqtig.org/downloads/berichte/2018/IQTIG_Qualitaetsreport-2019_2019-09-25.pdf</nowiki>, IQTIQ. Qualitätsreport. 2019.
*Hochspringen↑ Almirall, J., et al., Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest, 2004. 125(4): p. 1335-42.
*Hochspringen↑ Muller, F., et al., Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest, 2010. 138(1): p. 121-9.
*↑ Hochspringen nach:10,0 10,1 de With K, W.K., Kern WV et al S3-Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus. . 2018.
*Hochspringen↑ Forst, G., et al., Clinimetric properties and suitability of selected quality indicators for assessing antibiotic use in hospitalized adults: a multicentre point prevalence study in 24 hospitals in Germany. J Antimicrob Chemother, 2019. 74(12): p. 3596-3602.
*Hochspringen↑ Schuetz, P., et al., Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis, 2018. 18(1): p. 95-107.
*Hochspringen↑ <nowiki>https://link.springer.com/content/pdf/10.1007%2Fs00103-020-03123-w.pdf</nowiki>.
*Hochspringen↑ Torres, A., et al., Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease.Thorax, 2015. 70(10): p. 984-9.
*Hochspringen↑ Jensen, A.V., et al., Undiagnosed Diabetes Mellitus in Community-Acquired Pneumonia: A Prospective Cohort Study.Clin Infect Dis, 2017. 65(12): p. 2091-2098.


<br />
2. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T, CAPNETZ Study Group. CRB-65 predicts death from community-acquired pneumonia. J Intern Med. 2006;260(1):93-101. doi:10.1111/j.1365-2796.2006.01657.x


3. Chalmers JD, Taylor JK, Mandal P, et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis. 2011;53(6):503-511. doi:10.1093/cid/cir463


4. Dinh A, Ropers J, Duran C, et al. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet. 2021;397(10280):1195-1203. doi:10.1016/S0140-6736(21)00313-5


1. Bader FG, Schröder M, Kujath P, Muhl E, Bruch H-P, Eckmann C. Diffuse postoperative peritonitis -- value of diagnostic parameters and impact of early indication for relaparotomy. Eur J Med Res. 2009;14(11):491-496. doi:10.1186/2047-783x-14-11-491
5. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250. doi:10.1056/NEJM199701233360402


2. Blot S, Antonelli M, Arvaniti K, et al. Epidemiology of intra-abdominal infection and sepsis in critically ill patients: “AbSeS”, a multinational observational cohort study and ESICM Trials Group Project. Intensive Care Med. 2019;45(12):1703-1717. doi:10.1007/s00134-019-05819-3
6. Först G, Kern WV, Weber N, et al. Clinimetric properties and suitability of selected quality indicators for assessing antibiotic use in hospitalized adults: a multicentre point prevalence study in 24 hospitals in Germany. J Antimicrob Chemother. 2019;74(12):3596-3602. doi:10.1093/jac/dkz364


3. Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs. 2005;65(12):1611-1620. doi:10.2165/00003495-200565120-00002
7. Jensen AV, Faurholt-Jepsen D, Egelund GB, et al. Undiagnosed Diabetes Mellitus in Community-Acquired Pneumonia: A Prospective Cohort Study. Clin Infect Dis. 2017;65(12):2091-2098. doi:10.1093/cid/cix703


4. Blot S, De Waele JJ, Vogelaers D. Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs. 2012;72(6):e17-32. doi:10.2165/11599800-000000000-00000
8. Kolditz M, Ewig S, Schütte H, et al. Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med. 2015;278(2):193-202. doi:10.1111/joim.12349


5. Bodmann K-F, und die Expertenkommission der Infektliga. [Complicated intra-abdominal infections: pathogens, resistance. Recommendations of the Infectliga on antbiotic therapy]. Chirurg. 2010;81(1):38-49. doi:10.1007/s00104-009-1822-9
9. Laws H-J, Baumann U, Bogdan C, et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsbl. 2020;63(5):588-644. doi:10.1007/s00103-020-03123-w


6. Bosscha K, Reijnders K, Hulstaert PF, Algra A, van der Werken C. Prognostic scoring systems to predict outcome in peritonitis and intra-abdominal sepsis. Br J Surg. 1997;84(11):1532-1534.
10. Liapikou A, Ferrer M, Polverino E, et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis. 2009;48(4):377-385. doi:10.1086/596307


7. Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18 Suppl 7:19-37. doi:10.1111/1469-0691.12039
11. Moore M, Stuart B, Little P, et al. Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study. Eur Respir J. 2017;50(5):1700434. doi:10.1183/13993003.00434-2017


8. Cuenca-Estrella M, Verweij PE, Arendrup MC, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect. 2012;18 Suppl 7:9-18. doi:10.1111/1469-0691.12038
12. Müller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest. 2010;138(1):121-129. doi:10.1378/chest.09-2920


9. Eckmann C. [Antibiotic therapy of intra-abdominal infections in the era of multiresistance]. Chirurg. 2016;87(1):26-33. doi:10.1007/s00104-015-0106-9
13. Nagata N, Nikaido Y, Kido M, Ishibashi T, Sueishi K. Terminal pulmonary infections in patients with lung cancer. Chest. 1993;103(6):1739-1742. doi:10.1378/chest.103.6.1739


10. Laws H-J, Baumann U, Bogdan C, et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsbl. 2020;63(5):588-644. doi:10.1007/s00103-020-03123-w
14. Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95-107. doi:10.1016/S1473-3099(17)30592-3


11. León C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34(3):730-737. doi:10.1097/01.CCM.0000202208.37364.7D
15. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70(10):984-989. doi:10.1136/thoraxjnl-2015-206780


12. Montravers P, Leroy O, Eckmann C. Intra-abdominal candidiasis: it’s still a long way to get unquestionable data. Intensive Care Med. 2015;41(9):1682-1684. doi:10.1007/s00134-015-3894-y
16. Valvani A, Martin A, Devarajan A, Chandy D. Postobstructive pneumonia in lung cancer. Ann Transl Med. 2019;7(15):357. doi:10.21037/atm.2019.05.26


13. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220(6):751-758. doi:10.1097/00000658-199412000-00008
17. Qualitätsreport 2019. Published online 2019:246.


14. Ruhnke M, Rickerts V, Cornely OA, et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses. 2011;54(4):279-310. doi:10.1111/j.1439-0507.2011.02040.x
18. 092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf. Accessed July 9, 2021. <nowiki>https://www.awmf.org/uploads/tx_szleitlinien/092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf</nowiki>


15. Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg. 2017;12:29. doi:10.1186/s13017-017-0141-6


16. Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162


17. 092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf. Accessed August 9, 2021. <nowiki>https://www.awmf.org/uploads/tx_szleitlinien/092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf</nowiki>
1.
 
Almirall J, Bolíbar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. ''Chest''. 2004;125(4):1335-1342. doi:[https://doi.org/10.1378/chest.125.4.1335 10.1378/chest.125.4.1335]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.1378%2Fchest.125.4.1335&rft_id=info%3Apmid%2F15078743&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Contribution%20of%20C-reactive%20protein%20to%20the%20diagnosis%20and%20assessment%20of%20severity%20of%20community-acquired%20pneumonia&rft.jtitle=Chest&rft.stitle=Chest&rft.volume=125&rft.issue=4&rft.aufirst=Jordi&rft.aulast=Almirall&rft.au=Jordi%20Almirall&rft.au=Ignasi%20Bol%C3%ADbar&rft.au=Pere%20Toran&rft.au=Guillem%20Pera&rft.au=Xavier%20Boquet&rft.au=Xavier%20Balanz%C3%B3&rft.au=Goretti%20Sauca&rft.au=undefined&rft.date=2004-04&rft.pages=1335-1342&rft.spage=1335&rft.epage=1342&rft.issn=0012-3692&rft.language=eng"></span>
 
2.
 
Bauer TT, Ewig S, Marre R, Suttorp N, Welte T, CAPNETZ Study Group. CRB-65 predicts death from community-acquired pneumonia. ''J Intern Med''. 2006;260(1):93-101. doi:[https://doi.org/10.1111/j.1365-2796.2006.01657.x 10.1111/j.1365-2796.2006.01657.x]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.1111%2Fj.1365-2796.2006.01657.x&rft_id=info%3Apmid%2F16789984&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CRB-65%20predicts%20death%20from%20community-acquired%20pneumonia&rft.jtitle=Journal%20of%20Internal%20Medicine&rft.stitle=J%20Intern%20Med&rft.volume=260&rft.issue=1&rft.aufirst=T.%20T.&rft.aulast=Bauer&rft.au=T.%20T.%20Bauer&rft.au=S.%20Ewig&rft.au=R.%20Marre&rft.au=N.%20Suttorp&rft.au=T.%20Welte&rft.au=undefined&rft.date=2006-07&rft.pages=93-101&rft.spage=93&rft.epage=101&rft.issn=0954-6820&rft.language=eng"></span>
 
3.
 
Chalmers JD, Taylor JK, Mandal P, et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. ''Clin Infect Dis''. 2011;53(6):503-511. doi:[https://doi.org/10.1093/cid/cir463 10.1093/cid/cir463]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.1093%2Fcid%2Fcir463&rft_id=info%3Apmid%2F21865188&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Validation%20of%20the%20Infectious%20Diseases%20Society%20of%20America%2FAmerican%20Thoratic%20Society%20minor%20criteria%20for%20intensive%20care%20unit%20admission%20in%20community-acquired%20pneumonia%20patients%20without%20major%20criteria%20or%20contraindications%20to%20intensive%20care%20unit%20care&rft.jtitle=Clinical%20Infectious%20Diseases%3A%20An%20Official%20Publication%20of%20the%20Infectious%20Diseases%20Society%20of%20America&rft.stitle=Clin%20Infect%20Dis&rft.volume=53&rft.issue=6&rft.aufirst=James%20D.&rft.aulast=Chalmers&rft.au=James%20D.%20Chalmers&rft.au=Joanne%20K.%20Taylor&rft.au=Pallavi%20Mandal&rft.au=Gourab%20Choudhury&rft.au=Aran%20Singanayagam&rft.au=Ahsan%20R.%20Akram&rft.au=Adam%20T.%20Hill&rft.date=2011-09&rft.pages=503-511&rft.spage=503&rft.epage=511&rft.issn=1537-6591&rft.language=eng"></span>
 
4.
 
Dinh A, Ropers J, Duran C, et al. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. ''Lancet''. 2021;397(10280):1195-1203. doi:[https://doi.org/10.1016/S0140-6736(21)00313-5 10.1016/S0140-6736(21)00313-5]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.1016%2FS0140-6736(21)00313-5&rft_id=info%3Apmid%2F33773631&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Discontinuing%20%CE%B2-lactam%20treatment%20after%203%20days%20for%20patients%20with%20community-acquired%20pneumonia%20in%20non-critical%20care%20wards%20(PTC)%3A%20a%20double-blind%2C%20randomised%2C%20placebo-controlled%2C%20non-inferiority%20trial&rft.jtitle=Lancet%20(London%2C%20England)&rft.stitle=Lancet&rft.volume=397&rft.issue=10280&rft.aufirst=Aur%C3%A9lien&rft.aulast=Dinh&rft.au=Aur%C3%A9lien%20Dinh&rft.au=Jacques%20Ropers&rft.au=Clara%20Duran&rft.au=Benjamin%20Davido&rft.au=Laur%C3%A8ne%20Deconinck&rft.au=Morgan%20Matt&rft.au=Olivia%20Senard&rft.au=Aurore%20Lagrange&rft.au=Sabrina%20Makhloufi&rft.au=Guillaume%20Mellon&rft.au=Victoire%20de%20Lastours&rft.au=Fr%C3%A9d%C3%A9rique%20Bouchand&rft.au=Emmanuel%20Mathieu&rft.au=Jean-Emmanuel%20Kahn&rft.au=Elisabeth%20Rouveix&rft.au=Julie%20Grenet&rft.au=Jennifer%20Dumoulin&rft.au=Thierry%20Chinet&rft.au=Marion%20P%C3%A9pin&rft.au=V%C3%A9ronique%20Delcey&rft.au=Sylvain%20Diamantis&rft.au=Daniel%20Benhamou&rft.au=Virginie%20Vitrat&rft.au=Marie-Christine%20Dombret&rft.au=Bertrand%20Renaud&rft.au=Christian%20Perronne&rft.au=Yann-Erick%20Claessens&rft.au=Jos%C3%A9%20Labar%C3%A8re&rft.au=Jean-Pierre%20Bedos&rft.au=Philippe%20Aegerter&rft.au=Anne-Claude%20Cr%C3%A9mieux&rft.au=undefined&rft.date=2021-03-27&rft.pages=1195-1203&rft.spage=1195&rft.epage=1203&rft.issn=1474-547X&rft.language=eng"></span>
 
5.
 
Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. ''N Engl J Med''. 1997;336(4):243-250. doi:[https://doi.org/10.1056/NEJM199701233360402 10.1056/NEJM199701233360402]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.1056%2FNEJM199701233360402&rft_id=info%3Apmid%2F8995086&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A%20prediction%20rule%20to%20identify%20low-risk%20patients%20with%20community-acquired%20pneumonia&rft.jtitle=The%20New%20England%20Journal%20of%20Medicine&rft.stitle=N%20Engl%20J%20Med&rft.volume=336&rft.issue=4&rft.aufirst=M.%20J.&rft.aulast=Fine&rft.au=M.%20J.%20Fine&rft.au=T.%20E.%20Auble&rft.au=D.%20M.%20Yealy&rft.au=B.%20H.%20Hanusa&rft.au=L.%20A.%20Weissfeld&rft.au=D.%20E.%20Singer&rft.au=C.%20M.%20Coley&rft.au=T.%20J.%20Marrie&rft.au=W.%20N.%20Kapoor&rft.date=1997-01-23&rft.pages=243-250&rft.spage=243&rft.epage=250&rft.issn=0028-4793&rft.language=eng"></span>
 
6.
 
Först G, Kern WV, Weber N, et al. Clinimetric properties and suitability of selected quality indicators for assessing antibiotic use in hospitalized adults: a multicentre point prevalence study in 24 hospitals in Germany. ''J Antimicrob Chemother''. 2019;74(12):3596-3602. doi:[https://doi.org/10.1093/jac/dkz364 10.1093/jac/dkz364]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.1093%2Fjac%2Fdkz364&rft_id=info%3Apmid%2F31504603&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinimetric%20properties%20and%20suitability%20of%20selected%20quality%20indicators%20for%20assessing%20antibiotic%20use%20in%20hospitalized%20adults%3A%20a%20multicentre%20point%20prevalence%20study%20in%2024%20hospitals%20in%20Germany&rft.jtitle=The%20Journal%20of%20Antimicrobial%20Chemotherapy&rft.stitle=J%20Antimicrob%20Chemother&rft.volume=74&rft.issue=12&rft.aufirst=Gesche&rft.aulast=F%C3%B6rst&rft.au=Gesche%20F%C3%B6rst&rft.au=Winfried%20V.%20Kern&rft.au=Nadine%20Weber&rft.au=Christiane%20Querbach&rft.au=Johannes%20Kleideiter&rft.au=Holger%20Knoth&rft.au=Stefan%20Hagel&rft.au=Andreas%20Ambrosch&rft.au=Micha%20L%C3%B6bermann&rft.au=Philipp%20Schr%C3%B6der&rft.au=Johannes%20Borde&rft.au=Michaela%20Steib-Bauert&rft.au=Katja%20de%20With&rft.au=undefined&rft.date=2019-12-01&rft.pages=3596-3602&rft.spage=3596&rft.epage=3602&rft.issn=1460-2091&rft.language=eng"></span>
 
7.
 
Jensen AV, Faurholt-Jepsen D, Egelund GB, et al. Undiagnosed Diabetes Mellitus in Community-Acquired Pneumonia: A Prospective Cohort Study. ''Clin Infect Dis''. 2017;65(12):2091-2098. doi:[https://doi.org/10.1093/cid/cix703 10.1093/cid/cix703]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.1093%2Fcid%2Fcix703&rft_id=info%3Apmid%2F29095981&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Undiagnosed%20Diabetes%20Mellitus%20in%20Community-Acquired%20Pneumonia%3A%20A%20Prospective%20Cohort%20Study&rft.jtitle=Clinical%20Infectious%20Diseases%3A%20An%20Official%20Publication%20of%20the%20Infectious%20Diseases%20Society%20of%20America&rft.stitle=Clin%20Infect%20Dis&rft.volume=65&rft.issue=12&rft.aufirst=Andreas%20Vestergaard&rft.aulast=Jensen&rft.au=Andreas%20Vestergaard%20Jensen&rft.au=Daniel%20Faurholt-Jepsen&rft.au=Gertrud%20Baunb%C3%A6k%20Egelund&rft.au=Stine%20Bang%20Andersen&rft.au=Pelle%20Trier%20Petersen&rft.au=Thomas%20Benfield&rft.au=Martin%20Witzenrath&rft.au=Gernot%20Rohde&rft.au=Pernille%20Ravn&rft.au=undefined&rft.au=undefined&rft.date=2017-11-29&rft.pages=2091-2098&rft.spage=2091&rft.epage=2098&rft.issn=1537-6591&rft.language=eng"></span>
 
8.
 
Kolditz M, Ewig S, Schütte H, et al. Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. ''J Intern Med''. 2015;278(2):193-202. doi:[https://doi.org/10.1111/joim.12349 10.1111/joim.12349]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.1111%2Fjoim.12349&rft_id=info%3Apmid%2F25597400&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Assessment%20of%20oxygenation%20and%20comorbidities%20improves%20outcome%20prediction%20in%20patients%20with%20community-acquired%20pneumonia%20with%20a%20low%20CRB-65%20score&rft.jtitle=Journal%20of%20Internal%20Medicine&rft.stitle=J%20Intern%20Med&rft.volume=278&rft.issue=2&rft.aufirst=M.&rft.aulast=Kolditz&rft.au=M.%20Kolditz&rft.au=S.%20Ewig&rft.au=H.%20Sch%C3%BCtte&rft.au=N.%20Suttorp&rft.au=T.%20Welte&rft.au=G.%20Rohde&rft.au=undefined&rft.date=2015-08&rft.pages=193-202&rft.spage=193&rft.epage=202&rft.issn=1365-2796&rft.language=eng"></span>
 
9.
 
Laws H-J, Baumann U, Bogdan C, et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. ''Bundesgesundheitsbl''. 2020;63(5):588-644. doi:[https://doi.org/10.1007/s00103-020-03123-w 10.1007/s00103-020-03123-w]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.1007%2Fs00103-020-03123-w&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impfen%20bei%20Immundefizienz%3A%20Anwendungshinweise%20zu%20den%20von%20der%20St%C3%A4ndigen%20Impfkommission%20empfohlenen%20Impfungen.%20(III)%20Impfen%20bei%20h%C3%A4matologischen%20und%20onkologischen%20Erkrankungen%20(antineoplastische%20Therapie%2C%20Stammzelltransplantation)%2C%20Organtransplantation%20und%20Asplenie&rft.jtitle=Bundesgesundheitsblatt%20-%20Gesundheitsforschung%20-%20Gesundheitsschutz&rft.stitle=Bundesgesundheitsbl&rft.volume=63&rft.issue=5&rft.aufirst=Hans-J%C3%BCrgen&rft.aulast=Laws&rft.au=Hans-J%C3%BCrgen%20Laws&rft.au=Ulrich%20Baumann&rft.au=Christian%20Bogdan&rft.au=Gerd%20Burchard&rft.au=Maximilian%20Christopeit&rft.au=Jane%20Hecht&rft.au=Ulrich%20Heininger&rft.au=Inken%20Hilgendorf&rft.au=Winfried%20Kern&rft.au=Kerstin%20Kling&rft.au=Guido%20Kobbe&rft.au=Wiebe%20K%C3%BClper&rft.au=Thomas%20Lehrnbecher&rft.au=Roland%20Meisel&rft.au=Arne%20Simon&rft.au=Andrew%20Ullmann&rft.au=Maike%20de%20Wit&rft.au=Fred%20Zepp&rft.date=2020-05&rft.pages=588-644&rft.spage=588&rft.epage=644&rft.issn=1436-9990%2C%201437-1588&rft.language=de"></span>
 
10.
 
Liapikou A, Ferrer M, Polverino E, et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. ''Clin Infect Dis''. 2009;48(4):377-385. doi:[https://doi.org/10.1086/596307 10.1086/596307]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.1086%2F596307&rft_id=info%3Apmid%2F19140759&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Severe%20community-acquired%20pneumonia%3A%20validation%20of%20the%20Infectious%20Diseases%20Society%20of%20America%2FAmerican%20Thoracic%20Society%20guidelines%20to%20predict%20an%20intensive%20care%20unit%20admission&rft.jtitle=Clinical%20Infectious%20Diseases%3A%20An%20Official%20Publication%20of%20the%20Infectious%20Diseases%20Society%20of%20America&rft.stitle=Clin%20Infect%20Dis&rft.volume=48&rft.issue=4&rft.aufirst=Adamantia&rft.aulast=Liapikou&rft.au=Adamantia%20Liapikou&rft.au=Miquel%20Ferrer&rft.au=Eva%20Polverino&rft.au=Valentina%20Balasso&rft.au=Mariano%20Esperatti&rft.au=Raquel%20Pi%C3%B1er&rft.au=Jose%20Mensa&rft.au=Nestor%20Luque&rft.au=Santiago%20Ewig&rft.au=Rosario%20Menendez&rft.au=Michael%20S.%20Niederman&rft.au=Antoni%20Torres&rft.date=2009-02-15&rft.pages=377-385&rft.spage=377&rft.epage=385&rft.issn=1537-6591&rft.language=eng"></span>
 
11.
 
Moore M, Stuart B, Little P, et al. Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study. ''Eur Respir J''. 2017;50(5):1700434. doi:[https://doi.org/10.1183/13993003.00434-2017 10.1183/13993003.00434-2017]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.1183%2F13993003.00434-2017&rft_id=info%3Apmid%2F29167296&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predictors%20of%20pneumonia%20in%20lower%20respiratory%20tract%20infections%3A%203C%20prospective%20cough%20complication%20cohort%C2%A0study&rft.jtitle=The%20European%20Respiratory%20Journal&rft.stitle=Eur%20Respir%20J&rft.volume=50&rft.issue=5&rft.aufirst=Michael&rft.aulast=Moore&rft.au=Michael%20Moore&rft.au=Beth%20Stuart&rft.au=Paul%20Little&rft.au=Sue%20Smith&rft.au=Matthew%20J.%20Thompson&rft.au=Kyle%20Knox&rft.au=Anne%20van%20den%20Bruel&rft.au=Mark%20Lown&rft.au=David%20Mant&rft.date=2017-11&rft.pages=1700434&rft.issn=1399-3003&rft.language=eng"></span>
 
12.
 
Müller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. ''Chest''. 2010;138(1):121-129. doi:[https://doi.org/10.1378/chest.09-2920 10.1378/chest.09-2920]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.1378%2Fchest.09-2920&rft_id=info%3Apmid%2F20299634&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Procalcitonin%20levels%20predict%20bacteremia%20in%20patients%20with%20community-acquired%20pneumonia%3A%20a%20prospective%20cohort%20trial&rft.jtitle=Chest&rft.stitle=Chest&rft.volume=138&rft.issue=1&rft.aufirst=Fabian&rft.aulast=M%C3%BCller&rft.au=Fabian%20M%C3%BCller&rft.au=Mirjam%20Christ-Crain&rft.au=Thomas%20Bregenzer&rft.au=Martin%20Krause&rft.au=Werner%20Zimmerli&rft.au=Beat%20Mueller&rft.au=Philipp%20Schuetz&rft.au=undefined&rft.date=2010-07&rft.pages=121-129&rft.spage=121&rft.epage=129&rft.issn=1931-3543&rft.language=eng"></span>
 
13.
 
Nagata N, Nikaido Y, Kido M, Ishibashi T, Sueishi K. Terminal pulmonary infections in patients with lung cancer. ''Chest''. 1993;103(6):1739-1742. doi:[https://doi.org/10.1378/chest.103.6.1739 10.1378/chest.103.6.1739]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.1378%2Fchest.103.6.1739&rft_id=info%3Apmid%2F8404093&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Terminal%20pulmonary%20infections%20in%20patients%20with%20lung%20cancer&rft.jtitle=Chest&rft.stitle=Chest&rft.volume=103&rft.issue=6&rft.aufirst=N.&rft.aulast=Nagata&rft.au=N.%20Nagata&rft.au=Y.%20Nikaido&rft.au=M.%20Kido&rft.au=T.%20Ishibashi&rft.au=K.%20Sueishi&rft.date=1993-06&rft.pages=1739-1742&rft.spage=1739&rft.epage=1742&rft.issn=0012-3692&rft.language=eng"></span>
 
14.
 
Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. ''Lancet Infect Dis''. 2018;18(1):95-107. doi:[https://doi.org/10.1016/S1473-3099(17)30592-3 10.1016/S1473-3099(17)30592-3]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.1016%2FS1473-3099(17)30592-3&rft_id=info%3Apmid%2F29037960&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect%20of%20procalcitonin-guided%20antibiotic%20treatment%20on%20mortality%20in%20acute%20respiratory%20infections%3A%20a%20patient%20level%20meta-analysis&rft.jtitle=The%20Lancet.%20Infectious%20Diseases&rft.stitle=Lancet%20Infect%20Dis&rft.volume=18&rft.issue=1&rft.aufirst=Philipp&rft.aulast=Schuetz&rft.au=Philipp%20Schuetz&rft.au=Yannick%20Wirz&rft.au=Ramon%20Sager&rft.au=Mirjam%20Christ-Crain&rft.au=Daiana%20Stolz&rft.au=Michael%20Tamm&rft.au=Lila%20Bouadma&rft.au=Charles%20E.%20Luyt&rft.au=Michel%20Wolff&rft.au=Jean%20Chastre&rft.au=Florence%20Tubach&rft.au=Kristina%20B.%20Kristoffersen&rft.au=Olaf%20Burkhardt&rft.au=Tobias%20Welte&rft.au=Stefan%20Schroeder&rft.au=Vandack%20Nobre&rft.au=Long%20Wei&rft.au=Heiner%20C.%20Bucher&rft.au=Djillali%20Annane&rft.au=Konrad%20Reinhart&rft.au=Ann%20R.%20Falsey&rft.au=Angela%20Branche&rft.au=Pierre%20Damas&rft.au=Maarten%20Nijsten&rft.au=Dylan%20W.%20de%20Lange&rft.au=Rodrigo%20O.%20Deliberato&rft.au=Carolina%20F.%20Oliveira&rft.au=Vera%20Maravi%C4%87-Stojkovi%C4%87&rft.au=Alessia%20Verduri&rft.au=Bianca%20Begh%C3%A9&rft.au=Bin%20Cao&rft.au=Yahya%20Shehabi&rft.au=Jens-Ulrik%20S.%20Jensen&rft.au=Caspar%20Corti&rft.au=Jos%20A.%20H.%20van%20Oers&rft.au=Albertus%20Beishuizen&rft.au=Armand%20R.%20J.%20Girbes&rft.au=Evelien%20de%20Jong&rft.au=Matthias%20Briel&rft.au=Beat%20Mueller&rft.date=2018-01&rft.pages=95-107&rft.spage=95&rft.epage=107&rft.issn=1474-4457&rft.language=eng"></span>
 
15.
 
Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. ''Thorax''. 2015;70(10):984-989. doi:[https://doi.org/10.1136/thoraxjnl-2015-206780 10.1136/thoraxjnl-2015-206780]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.1136%2Fthoraxjnl-2015-206780&rft_id=info%3Apmid%2F26219979&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Which%20individuals%20are%20at%20increased%20risk%20of%20pneumococcal%20disease%20and%20why%3F%20Impact%20of%20COPD%2C%20asthma%2C%20smoking%2C%20diabetes%2C%20and%2For%20chronic%20heart%20disease%20on%20community-acquired%20pneumonia%20and%20invasive%20pneumococcal%20disease&rft.jtitle=Thorax&rft.stitle=Thorax&rft.volume=70&rft.issue=10&rft.aufirst=Antoni&rft.aulast=Torres&rft.au=Antoni%20Torres&rft.au=Francesco%20Blasi&rft.au=Nathalie%20Dartois&rft.au=Murat%20Akova&rft.date=2015-10&rft.pages=984-989&rft.spage=984&rft.epage=989&rft.issn=1468-3296&rft.language=eng"></span>
 
16.
 
Valvani A, Martin A, Devarajan A, Chandy D. Postobstructive pneumonia in lung cancer. ''Ann Transl Med''. 2019;7(15):357. doi:[https://doi.org/10.21037/atm.2019.05.26 10.21037/atm.2019.05.26]
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_id=info%3Adoi%2F10.21037%2Fatm.2019.05.26&rft_id=info%3Apmid%2F31516903&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Postobstructive%20pneumonia%20in%20lung%20cancer&rft.jtitle=Annals%20of%20Translational%20Medicine&rft.stitle=Ann%20Transl%20Med&rft.volume=7&rft.issue=15&rft.aufirst=Aashish&rft.aulast=Valvani&rft.au=Aashish%20Valvani&rft.au=Alvaro%20Martin&rft.au=Anusha%20Devarajan&rft.au=Dipak%20Chandy&rft.date=2019-08&rft.pages=357&rft.issn=2305-5839&rft.language=eng"></span>
 
17.
 
Qualitätsreport 2019. Published online 2019:246.
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Qualit%C3%A4tsreport%202019&rft.date=2019&rft.pages=246&rft.language=de"></span>
 
18.
 
092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf. Accessed July 9, 2021. https://www.awmf.org/uploads/tx_szleitlinien/092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf
 
<span class="Z3988" title="url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&rfr_id=info%3Asid%2Fzotero.org%3A2&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rft.type=attachment&rft.title=092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf&rft.identifier=https%3A%2F%2Fwww.awmf.org%2Fuploads%2Ftx_szleitlinien%2F092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf"></span><br />

Revision as of 17:18, 9 August 2021

1. Almirall J, Bolíbar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004;125(4):1335-1342. doi:10.1378/chest.125.4.1335

2. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T, CAPNETZ Study Group. CRB-65 predicts death from community-acquired pneumonia. J Intern Med. 2006;260(1):93-101. doi:10.1111/j.1365-2796.2006.01657.x

3. Chalmers JD, Taylor JK, Mandal P, et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis. 2011;53(6):503-511. doi:10.1093/cid/cir463

4. Dinh A, Ropers J, Duran C, et al. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet. 2021;397(10280):1195-1203. doi:10.1016/S0140-6736(21)00313-5

5. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250. doi:10.1056/NEJM199701233360402

6. Först G, Kern WV, Weber N, et al. Clinimetric properties and suitability of selected quality indicators for assessing antibiotic use in hospitalized adults: a multicentre point prevalence study in 24 hospitals in Germany. J Antimicrob Chemother. 2019;74(12):3596-3602. doi:10.1093/jac/dkz364

7. Jensen AV, Faurholt-Jepsen D, Egelund GB, et al. Undiagnosed Diabetes Mellitus in Community-Acquired Pneumonia: A Prospective Cohort Study. Clin Infect Dis. 2017;65(12):2091-2098. doi:10.1093/cid/cix703

8. Kolditz M, Ewig S, Schütte H, et al. Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med. 2015;278(2):193-202. doi:10.1111/joim.12349

9. Laws H-J, Baumann U, Bogdan C, et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsbl. 2020;63(5):588-644. doi:10.1007/s00103-020-03123-w

10. Liapikou A, Ferrer M, Polverino E, et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis. 2009;48(4):377-385. doi:10.1086/596307

11. Moore M, Stuart B, Little P, et al. Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study. Eur Respir J. 2017;50(5):1700434. doi:10.1183/13993003.00434-2017

12. Müller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest. 2010;138(1):121-129. doi:10.1378/chest.09-2920

13. Nagata N, Nikaido Y, Kido M, Ishibashi T, Sueishi K. Terminal pulmonary infections in patients with lung cancer. Chest. 1993;103(6):1739-1742. doi:10.1378/chest.103.6.1739

14. Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95-107. doi:10.1016/S1473-3099(17)30592-3

15. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70(10):984-989. doi:10.1136/thoraxjnl-2015-206780

16. Valvani A, Martin A, Devarajan A, Chandy D. Postobstructive pneumonia in lung cancer. Ann Transl Med. 2019;7(15):357. doi:10.21037/atm.2019.05.26

17. Qualitätsreport 2019. Published online 2019:246.

18. 092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf. Accessed July 9, 2021. https://www.awmf.org/uploads/tx_szleitlinien/092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf


1.

Almirall J, Bolíbar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004;125(4):1335-1342. doi:10.1378/chest.125.4.1335

2.

Bauer TT, Ewig S, Marre R, Suttorp N, Welte T, CAPNETZ Study Group. CRB-65 predicts death from community-acquired pneumonia. J Intern Med. 2006;260(1):93-101. doi:10.1111/j.1365-2796.2006.01657.x

3.

Chalmers JD, Taylor JK, Mandal P, et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis. 2011;53(6):503-511. doi:10.1093/cid/cir463

4.

Dinh A, Ropers J, Duran C, et al. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet. 2021;397(10280):1195-1203. doi:10.1016/S0140-6736(21)00313-5

5.

Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250. doi:10.1056/NEJM199701233360402

6.

Först G, Kern WV, Weber N, et al. Clinimetric properties and suitability of selected quality indicators for assessing antibiotic use in hospitalized adults: a multicentre point prevalence study in 24 hospitals in Germany. J Antimicrob Chemother. 2019;74(12):3596-3602. doi:10.1093/jac/dkz364

7.

Jensen AV, Faurholt-Jepsen D, Egelund GB, et al. Undiagnosed Diabetes Mellitus in Community-Acquired Pneumonia: A Prospective Cohort Study. Clin Infect Dis. 2017;65(12):2091-2098. doi:10.1093/cid/cix703

8.

Kolditz M, Ewig S, Schütte H, et al. Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med. 2015;278(2):193-202. doi:10.1111/joim.12349

9.

Laws H-J, Baumann U, Bogdan C, et al. Impfen bei Immundefizienz: Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie. Bundesgesundheitsbl. 2020;63(5):588-644. doi:10.1007/s00103-020-03123-w

10.

Liapikou A, Ferrer M, Polverino E, et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis. 2009;48(4):377-385. doi:10.1086/596307

11.

Moore M, Stuart B, Little P, et al. Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study. Eur Respir J. 2017;50(5):1700434. doi:10.1183/13993003.00434-2017

12.

Müller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest. 2010;138(1):121-129. doi:10.1378/chest.09-2920

13.

Nagata N, Nikaido Y, Kido M, Ishibashi T, Sueishi K. Terminal pulmonary infections in patients with lung cancer. Chest. 1993;103(6):1739-1742. doi:10.1378/chest.103.6.1739

14.

Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95-107. doi:10.1016/S1473-3099(17)30592-3

15.

Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70(10):984-989. doi:10.1136/thoraxjnl-2015-206780

16.

Valvani A, Martin A, Devarajan A, Chandy D. Postobstructive pneumonia in lung cancer. Ann Transl Med. 2019;7(15):357. doi:10.21037/atm.2019.05.26

17.

Qualitätsreport 2019. Published online 2019:246.

18.

092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf. Accessed July 9, 2021. https://www.awmf.org/uploads/tx_szleitlinien/092-001l_S3_Strategien-zur-Sicherung-rationaler-Antibiotika-Anwendung-im-Krankenhaus_2020-02.pdf


Retrieved from "https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Ambulant_erworbene_Pneumonie/Quellen&oldid=1382"